ATE212854T1 - Verfahren zur behandlung von festhaltenden lungensekreten - Google Patents

Verfahren zur behandlung von festhaltenden lungensekreten

Info

Publication number: ATE212854T1
Authority: AT; Austria
Prior art keywords: lantibiotic; subject; treating; retentional; secrets
Prior art date: 1993-06-09

Application number

AT94919422T

Other languages

English (en)

Inventor

Y Vedia Luis M Molina

Monroe Jackson Stutts

Richard C Boucher Jr

David C Henke

Original Assignee

Molichem Medicines Inc

Univ North Carolina

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-09

Filing date

1994-06-08

Publication date

2002-02-15

1994-06-08 Application filed by Molichem Medicines Inc, Univ North Carolina filed Critical Molichem Medicines Inc

2002-02-15 Application granted granted Critical

2002-02-15 Publication of ATE212854T1 publication Critical patent/ATE212854T1/de

Links

210000004072 lung Anatomy 0.000 title abstract 2
108010062877 Bacteriocins Proteins 0.000 abstract 5
206010006458 Bronchitis chronic Diseases 0.000 abstract 1
201000003883 Cystic fibrosis Diseases 0.000 abstract 1
239000000443 aerosol Substances 0.000 abstract 1
206010006451 bronchitis Diseases 0.000 abstract 1
208000023819 chronic asthma Diseases 0.000 abstract 1
208000007451 chronic bronchitis Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
108010067071 duramycin Proteins 0.000 abstract 1
SFWLDKQAUHFCBS-WWXQEMPQSA-N lancovutide Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@@H](CCCCNC[C@H]4C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)N[C@H]([C@@H](SC[C@H](NC(=O)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSC3C)CSC2)C(=O)N4)C)C(=O)N1)C(O)=O)[C@@H](O)C(O)=O)=O)C(C)C)C1=CC=CC=C1 SFWLDKQAUHFCBS-WWXQEMPQSA-N 0.000 abstract 1
230000002685 pulmonary effect Effects 0.000 abstract 1
230000000241 respiratory effect Effects 0.000 abstract 1
230000000717 retained effect Effects 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1
201000008827 tuberculosis Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Magnetic Resonance Imaging Apparatus (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Steroid Compounds (AREA)

AT94919422T 1993-06-09 1994-06-08 Verfahren zur behandlung von festhaltenden lungensekreten ATE212854T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/074,315 US5512269A (en)	1993-06-09	1993-06-09	Method of treating retained pulmonary secretions
PCT/US1994/006486 WO1994028726A2 (en)	1993-06-09	1994-06-08	Method of treating retained pulmonary secretions

Publications (1)

Publication Number	Publication Date
ATE212854T1 true ATE212854T1 (de)	2002-02-15

Family

ID=22118924

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94919422T ATE212854T1 (de)	1993-06-09	1994-06-08	Verfahren zur behandlung von festhaltenden lungensekreten

Country Status (11)

Country	Link
US (5)	US5512269A (de)
EP (2)	EP0764028B1 (de)
JP (2)	JP4027968B2 (de)
AT (1)	ATE212854T1 (de)
AU (1)	AU696374B2 (de)
CA (1)	CA2164517C (de)
DE (1)	DE69429832T2 (de)
DK (1)	DK0764028T3 (de)
ES (1)	ES2170769T3 (de)
PT (1)	PT764028E (de)
WO (1)	WO1994028726A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5656256A (en) *	1994-12-14	1997-08-12	The University Of North Carolina At Chapel Hill	Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5908611A (en) *	1995-05-05	1999-06-01	The Scripps Research Institute	Treatment of viscous mucous-associated diseases
US5635160A (en) *	1995-06-07	1997-06-03	The University Of North Carolina At Chapel Hill	Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5866539A (en) *	1995-06-23	1999-02-02	Ambi Inc.	Method for the control of antibiotic-resistant gram positive bacteria and treatment of infection
US5910479A (en) *	1996-10-18	1999-06-08	Ambi Inc.	Method for the treatment of Streptococcus pneumoniae infection
DE19745583A1 (de) *	1997-10-15	1999-04-22	Hoechst Marion Roussel De Gmbh	Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
CA2332369A1 (en) *	1998-05-27	1999-12-02	Euroceltique S.A.	Drug delivery system comprising a tightly compacted solid medicament stock
US6323191B1 (en)	1998-06-19	2001-11-27	Genzyme Corporation	Small molecule chloride transport
BR9912053A (pt) *	1998-07-13	2001-04-03	Univ Texas	Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
US6818213B1 (en) *	1998-07-13	2004-11-16	Board Of Regents, The University Of Texas System	Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
TW465235B (en)	1998-09-17	2001-11-21	United Video Properties Inc	Electronic program guide with digital storage
CN1348377A (zh) *	1998-12-17	2002-05-08	希龙公司	用气溶胶化的抗生素治疗严重慢性支气管炎(支气管扩张症)的方法
US8501911B2 (en) *	1999-02-24	2013-08-06	Biomarck Pharmaceuticals, Ltd	Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en)	2001-06-26	2009-06-09	Biomarck Pharmaceuticals, Ltd.	Methods for regulating inflammatory mediators and peptides useful therein
JP4969002B2 (ja) *	1999-06-08	2012-07-04	ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン	ｒＡＡＶ形質導入を増加するための化合物および方法
US20020061281A1 (en) *	1999-07-06	2002-05-23	Osbakken Robert S.	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) *	1999-07-06	2003-06-10	Sinuspharma, Inc.	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6245320B1 (en) *	1999-09-01	2001-06-12	University Of Maryland	Inhibition of mucin release from airway goblet cells by polycationic peptides
US7241447B1 (en) *	1999-10-07	2007-07-10	University Of Iowa Research Foundation	Adeno-associated virus vectors and uses thereof
US7919469B2 (en)	2000-02-24	2011-04-05	North Carolina State University	Methods and compositions for altering mucus secretion
US7265088B1 (en)	2000-02-24	2007-09-04	North Carolina State University	Method and compositions for altering mucus secretion
US6858615B2 (en)	2002-02-19	2005-02-22	Parion Sciences, Inc.	Phenyl guanidine sodium channel blockers
CN1642524B (zh) *	2002-03-12	2011-05-18	微计量治疗公司	通过吸入部位特异性递送联合施用的药物
US7511124B2 (en) *	2002-07-15	2009-03-31	Board Of Regents, The University Of Texas System	Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7378386B2 (en) *	2002-07-15	2008-05-27	Board Of Regents, The University Of Texas System	Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives
DE60335383D1 (de)	2002-07-15	2011-01-27	Univ Texas	Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
US7384909B2 (en)	2002-07-15	2008-06-10	Board Of Regents, The University Of Texas System	Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7879801B2 (en) *	2002-07-15	2011-02-01	Board Of Regents, The University Of Texas System	Compositions comprising cell-impermeant duramycin derivatives
US7678386B2 (en)	2002-07-15	2010-03-16	Board Of Regents The University Of Texas	Liposomes coated with selected antibodies that bind to aminophospholipids
US7828739B2 (en) *	2002-08-27	2010-11-09	Precision Pulsus, Inc.	Apnea detection system
US6869402B2 (en) *	2002-08-27	2005-03-22	Precision Pulsus, Inc.	Method and apparatus for measuring pulsus paradoxus
EP1558746A4 (de) *	2002-10-10	2006-11-22	Molichem Medicines Inc	Duramycin codierende nukleinsäuren
MXPA05004121A (es) *	2002-10-18	2006-02-17	Molichem Medicines Inc	Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
DE10261782A1 (de) *	2002-12-19	2004-07-01	Dr. Petry Genmedics Gmbh	Neue Gene und Genprodukte
WO2004080427A2 (en) *	2003-03-12	2004-09-23	Schneider Daniel J	Method of preventing and treating infections that attack mucosa and assisting rehabilitation thereafter using topically applied ascorbic acid
WO2004089423A2 (en) *	2003-03-31	2004-10-21	University Of Iowa Research Foundation	Pharmico-gene theraphy of epithelial sodium channel associated disoders
US7745442B2 (en)	2003-08-20	2010-06-29	Parion Sciences, Inc.	Methods of reducing risk of infection from pathogens
US20090253714A1 (en) *	2003-08-20	2009-10-08	Johnson Michael R	Methods of reducing risk of infection from pathogens
CA2565545A1 (en) *	2004-05-06	2005-12-08	Molichem Medicines, Inc.	Treatment of ocular diseases and disorders using lantibiotic compositions
WO2005107787A1 (en) *	2004-05-06	2005-11-17	Molichem Medicines, Inc.	Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
WO2006078899A2 (en)	2005-01-20	2006-07-27	Biomarck Pharmaceuticals, Ltd.	Mucin hypersecretion inhibitors based on the structure of mans and methods of use
US20070021439A1 (en) *	2005-07-25	2007-01-25	Parion Sciences, Inc.	Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
AU2006297289B2 (en)	2005-09-29	2013-03-21	Novartis Ag	Antibiotic formulations, unit doses, kits, and methods
WO2007076053A2 (en) *	2005-12-21	2007-07-05	Nitrox, Llc	Stable s-nitrosothiol formulations
GB0600928D0 (en)	2006-01-17	2006-02-22	Novacta Biosystems Ltd	Improvements relating to lantibiotics
WO2007092582A2 (en) *	2006-02-08	2007-08-16	Biosynexus Incorporated	Neutralization of bacterial spores
EP2019964A2 (de) *	2006-04-28	2009-02-04	University of Iowa Research Foundation	Verfahren und verbindungen zur modulation der parvovirusübertragung von säugerzellen oder zur änderung von virusinfektionen verfahren zur identifizierung eines viralen rezeptors oder co-rezeptors
SG10201500418QA (en)	2006-07-26	2015-03-30	Biomarck Pharmaceuticals Ltd	Methods for attenuating release of inflammatory mediators and peptides useful therein
US20080138397A1 (en) *	2006-10-24	2008-06-12	Aradigm Corporation	Processes for taste-masking of inhaled formulations
GB0714030D0 (en)	2007-07-18	2007-08-29	Novacta Biosystems Ltd	The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en)	2007-07-18	2007-08-29	Novacta Biosystems Ltd	Lantibiotic-based compounds having antimicrobial activity
WO2009141264A2 (en) *	2008-05-20	2009-11-26	Boehringer Ingelheim Vetmedica Gmbh	Gallidermin to treat infections of the respiratory tract
DK2387580T3 (da)	2009-01-14	2014-10-13	Novacta Biosystems Ltd	Deoxyactagardinderivater
EA020733B1 (ru)	2009-02-04	2015-01-30	Новакта Биосистемс Лимитед	Производные актагардина
CN102665807A (zh)	2010-01-05	2012-09-12	微剂量治疗技术公司	吸入设备和方法
GB201001688D0 (en)	2010-02-02	2010-03-17	Novacta Biosystems Ltd	Compounds
GB201013513D0 (en) *	2010-08-11	2010-09-22	Novacta Biosystems Ltd	Formulations
AR086745A1 (es)	2011-06-27	2014-01-22	Parion Sciences Inc	3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
RU2671976C2 (ru)	2012-12-17	2018-11-08	Пэрион Сайенсиз, Инк.	Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
HUE032891T2 (hu)	2012-12-17	2017-11-28	Parion Sciences Inc	Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
US9102633B2 (en)	2013-12-13	2015-08-11	Parion Sciences, Inc.	Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2017139381A1 (en)	2016-02-08	2017-08-17	University Of Iowa Research Foundation	Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
WO2017155973A1 (en)	2016-03-07	2017-09-14	University Of Iowa Research Foundation	Aav-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en)	2016-05-26	2024-12-24	University Of Iowa Research Foundation	cis and trans requirements for terminal resolution of human bocavirus 1
US11142775B2 (en)	2017-01-13	2021-10-12	University Of Iowa Research Foundation	Bocaparvovirus small noncoding RNA and uses thereof
CN114302706A (zh)	2019-06-17	2022-04-08	碧奥马尔克制药有限公司	治疗葡萄膜炎的肽及其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3683072A (en) *	1968-03-14	1972-08-08	William J Miller	A methobottromycin and process for treating poultry infections
US4501729A (en) *	1982-12-13	1985-02-26	Research Corporation	Aerosolized amiloride treatment of retained pulmonary secretions
JPS6234923A (ja) *	1985-08-09	1987-02-14	Hitachi Ltd	新規な重合体
ES2032831T5 (es) *	1986-08-19	2001-02-16	Genentech Inc	Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
ATE101490T1 (de) *	1988-06-22	1994-03-15	Applied Microbiology Inc	Nisin-zusammensetzungen zur anwendung als erhoehte breit-spektrum-bakterizide.
US5135910A (en) *	1988-06-22	1992-08-04	The Public Health Research Institute Of The City Of New York	Nisin compositions for use as enhanced, broad range bactericides
US4980163A (en) *	1989-03-01	1990-12-25	Public Health Research Institute Of The City Of New York	Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection
DE3938140A1 (de) *	1989-11-16	1991-08-08	Beiersdorf Ag	Desodorierende kosmetische mittel
JPH05963A (ja) *	1990-04-13	1993-01-08	Toray Ind Inc	ポリペプチド類組成物
US5162348A (en) *	1990-05-24	1992-11-10	Imperial Chemical Industries Plc	Treatment of cystic fibrosis
GB9105705D0 (en) *	1991-03-18	1991-05-01	Sandoz Ltd	Improvements in or relating to organic compounds
JPH05500229A (ja) *	1991-04-12	1993-01-21	東レ株式会社	固体ポリペプチド微粒子のエアロゾル製剤とその製造方法
US5559096A (en) *	1991-04-15	1996-09-24	Applied Microbiology, Inc.	Pharmaceutical compositions against gastric disorders
US5292498A (en) *	1991-06-19	1994-03-08	The University Of North Carolina At Chapel Hill	Method of treating lung disease with uridine triphosphates
US5384128A (en) *	1993-03-02	1995-01-24	University Of Alabama Research Foundation	Method of and compounds for treatment for cystic fibrosis

1993
- 1993-06-09 US US08/074,315 patent/US5512269A/en not_active Expired - Lifetime
1994
- 1994-06-08 PT PT94919422T patent/PT764028E/pt unknown
- 1994-06-08 ES ES94919422T patent/ES2170769T3/es not_active Expired - Lifetime
- 1994-06-08 EP EP94919422A patent/EP0764028B1/de not_active Expired - Lifetime
- 1994-06-08 AU AU70578/94A patent/AU696374B2/en not_active Ceased
- 1994-06-08 WO PCT/US1994/006486 patent/WO1994028726A2/en not_active Ceased
- 1994-06-08 JP JP50208395A patent/JP4027968B2/ja not_active Expired - Fee Related
- 1994-06-08 DK DK94919422T patent/DK0764028T3/da active
- 1994-06-08 DE DE69429832T patent/DE69429832T2/de not_active Expired - Fee Related
- 1994-06-08 CA CA002164517A patent/CA2164517C/en not_active Expired - Fee Related
- 1994-06-08 AT AT94919422T patent/ATE212854T1/de not_active IP Right Cessation
- 1994-06-08 EP EP01202315A patent/EP1166794A3/de not_active Withdrawn
1995
- 1995-05-02 US US08/431,659 patent/US5716931A/en not_active Expired - Fee Related
- 1995-05-02 US US08/432,984 patent/US5651957A/en not_active Expired - Lifetime
- 1995-05-02 US US08/433,872 patent/US5683675A/en not_active Expired - Lifetime
1998
- 1998-01-28 US US09/014,757 patent/US5849706A/en not_active Expired - Fee Related
2005
- 2005-04-12 JP JP2005114729A patent/JP2005206612A/ja active Pending

Also Published As

Publication number	Publication date
US5716931A (en)	1998-02-10
US5849706A (en)	1998-12-15
WO1994028726A2 (en)	1994-12-22
ES2170769T3 (es)	2002-08-16
DK0764028T3 (da)	2002-03-18
DE69429832T2 (de)	2002-08-14
WO1994028726A3 (en)	1995-03-02
CA2164517A1 (en)	1994-12-22
PT764028E (pt)	2002-06-28
EP0764028B1 (de)	2002-02-06
JP2005206612A (ja)	2005-08-04
JPH09501413A (ja)	1997-02-10
US5651957A (en)	1997-07-29
EP1166794A2 (de)	2002-01-02
US5512269A (en)	1996-04-30
EP1166794A3 (de)	2003-03-12
EP0764028A2 (de)	1997-03-26
DE69429832D1 (de)	2002-03-21
AU696374B2 (en)	1998-09-10
US5683675A (en)	1997-11-04
JP4027968B2 (ja)	2007-12-26
CA2164517C (en)	2010-01-19
AU7057894A (en)	1995-01-03

Legal Events

Date	Code	Title	Description
2002-12-15	UEP	Publication of translation of european patent specification
2010-03-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69429832D1 (de)	2002-03-21	Verfahren zur behandlung von festhaltenden lungensekreten
ATE223230T1 (de)	2002-09-15	Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1
EA200100338A1 (ru)	2001-10-22	Способ и устройство для введения действующего вещества в виде аэрозоли в легкие пациента
CA2146954A1 (en)	1996-10-13	Breath activated nicotine inhalers
GB9425160D0 (en)	1995-02-08	Medicaments
ATE269731T1 (de)	2004-07-15	Behandlung von pulmonaler vasokonstriktion und asthma
MX9605650A (es)	1998-05-31	Formulaciones de propionato de fluticasona.
TW329387B (en)	1998-04-11	Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
DK0656206T3 (da)	2001-10-08	Aerosolformuleringer uden chlorfluorcarbonforbindelser
DE69518334D1 (de)	2000-09-14	Pharmazeutische aerosol welche mindestens ein zucker enthält
BG102689A (bg)	1999-02-26	Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
GB2128088B (en)	1986-04-30	Oral mopidamol preparations
ES2082732T1 (es)	1996-04-01	Dispositivos para tratar la vasoconstriccion pulmonar y el asma.
EA200000823A1 (ru)	2001-02-26	Способ и устройство для подачи действующего вещества в виде аэрозоли
NZ330482A (en)	1999-11-29	Compositions comprising formoterol and budesonide for treating respiratory disorders
BG105391A (bg)	2001-11-30	Устойчив на съхранение концентрат на активно вещество формотерол
DE69018092D1 (de)	1995-04-27	Aerosolzubereitung von glutathion und verfahren zur erhöhung des glutathionspiegels in der lunge.
ATE229799T1 (de)	2003-01-15	Verwendung von phospholipiden zur herstellung eines arzneimittels zur behandlung von asthma
HUP9902675A2 (hu)	2000-01-28	Fluorozott-szénhidrogén-hajtógázt tartalmazó mometazon-furoát aeroszol
WO2000045834A3 (en)	2000-12-21	Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
ATE169225T1 (de)	1998-08-15	Anwendung von urodilatin bei lungen- und bronchialerkrankungen
MY117918A (en)	2004-08-30	Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
Sataloff	1996	Laryngoscope--Pollution: Consequences for Singers
Sataloff	2001	Essay the impact of pollution on the voice
RU2001125081A (ru)	2003-05-20	Способ лечения бронхиальной астмы